Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
αDC1-DLK1 vaccine
- Development stage
- Preclinical
- Lead developer
- University of Pittsburgh
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
αDC1-DLK1 vaccine is an experimental, preclinical cell-based cancer immunotherapy. It is a therapeutic dendritic cell vaccine consisting of alpha-type-1 polarized dendritic cells (αDC1) pulsed with a peptide derived from delta-like 1 homologue (DLK1), a pericyte marker on tumor-derived blood vessels. The vaccine is designed to prime cytotoxic T cells against DLK1-expressing tumor vasculature, thereby ablating the tumor blood supply. In preclinical models of colorectal cancer and triple-negative breast cancer (TNBC), the vaccine has demonstrated anti-tumor and anti-metastatic activity, particularly when combined with immune checkpoint blockade (such as anti-PD-1 therapy).
- Other names
- alpha-type-1 polarized dendritic cell DLK1 vaccinealpha-type1 polarized dendritic cell DLK1 vaccinealpha-type 1 polarized dendritic cell DLK1 vaccineαDC-DLK1 vaccineαDC1-DLK1
02
Targets
DLK1 (Delta-like homolog 1)MHC I (MHC class I})NOTCH (Neurogenic locus notch homolog protein 3)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on αDC1-DLK1 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on αDC1-DLK1 vaccine.